Sep 17, 2007 -Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) announced that it held an investigator meeting yesterday at the Interscience Conference on Antimicrobial Agents and Chemotherapy in Chicago...Sixteen medical centers and clinics across the United States are participating in the current Phase II trial, which is a 60-patient, randomized and open-label Phase II study to evaluate the preliminary safety and efficacy of topical Microcyn(R) Technology for the treatment of mildly infected diabetic foot infections... Oculus Innovative Sciences' Press Release -
Tuesday, September 18, 2007
Oculus Innovative Sciences, Phase II Study for Microcyn(R) Technology in Mildly Infected Diabetic Foot Ulcers
Sep 17, 2007 -Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) announced that it held an investigator meeting yesterday at the Interscience Conference on Antimicrobial Agents and Chemotherapy in Chicago...Sixteen medical centers and clinics across the United States are participating in the current Phase II trial, which is a 60-patient, randomized and open-label Phase II study to evaluate the preliminary safety and efficacy of topical Microcyn(R) Technology for the treatment of mildly infected diabetic foot infections... Oculus Innovative Sciences' Press Release -
